help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on November 3, 2009
Endocrinology, doi:10.1210/en.2009-0726
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Ribet, C.
Right arrow Articles by Langin, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribet, C.
Right arrow Articles by Langin, D.

Submitted on June 24, 2009
Accepted on October 9, 2009

Peroxisome Proliferator-Activated Receptor-{alpha} Control of Lipid and Glucose Metabolism in Human White Adipocytes

Carole Ribet, Emilie Montastier, Carine Valle, Véronic Bezaire, Anne Mazzucotelli, Aline Mairal, Nathalie Viguerie, and Dominique Langin*

Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 858 (C.R., E.M., C.V., V.B., A.Maz., A.Mai., N.V., D.L.), Obesity Research Laboratory, and Université de Toulouse, Paul Sabatier University, Rangueil Institute of Molecular Medicine (I2MR), Institut Fédératif de Recherche 150, F-31432 Toulouse, France; and Centre Hospitalier Universitaire de Toulouse (D.L.), Biochemistry Laboratory, Biology Institute of Purpan, F-31059 Toulouse, France

* To whom correspondence should be addressed. E-mail: dominique.langin{at}inserm.fr.

This work aimed at characterizing the role of peroxisome proliferator-activated receptors (PPAR){alpha} in human white adipocyte metabolism and at comparing PPAR{alpha} and PPAR{gamma} actions in these cells. Primary cultures of human fat cells were treated with the PPAR{alpha} agonist GW7647 or the PPAR{gamma} agonist rosiglitazone. Changes in gene expression were determined using DNA microrrays and quantitative RT-PCR. Western blot and metabolic studies were performed to identify the biological effects elicited by PPAR agonist treatments. GW7647 induced an up-regulation of {beta}-oxidation gene expression and increased palmitate oxidation. Unexpectedly, glycolysis was strongly reduced at transcriptional and functional levels by GW7647 leading to a decrease in pyruvate and lactate production. Glucose oxidation was decreased. Triglyceride esterification and de novo lipogenesis were inhibited by the PPAR{alpha} agonist. GW7647-induced alterations were abolished by a treatment with a PPAR{alpha} antagonist. Small interfering RNA-mediated extinction of PPAR{alpha} gene expression in hMADS adipocytes attenuated GW7647 induction of palmitate oxidation. Rosiglitazone had no major impact on glycolysis and {beta}-oxidation. Altogether these results show that PPAR{alpha} can selectively up-regulate {beta}-oxidation and decrease glucose utilization in human white adipocytes.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society